Lupin has received a warning letter from the United States Food and Drug Administration (USFDA) for the company’s Somerset, New Jersey facility. The USFDA had inspected the Lupin Somerset site from September 10, 2020 to November 5, 2020. The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1906.05 |
| Dr. Reddys Labs. | 1359.00 |
| Cipla | 1460.55 |
| Zydus Lifesciences | 1146.95 |
| Lupin | 2484.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: